Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Zamek-Gliszczynski MJ, Taub ME, Chothe PP, Chu X, Giacomini KM, Kim RB, Ray AS, Stocker SL, Unadkat JD, Wittwer MB, Xia C, Yee SW, Zhang L, Zhang Y; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):890-899. doi: 10.1002/cpt.1112. Epub 2018 Aug 8. Review.

PMID:
30091177
2.

Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling.

Mitra P, Weinheimer S, Michalewicz M, Taub ME.

Drug Metab Dispos. 2018 Jul;46(7):953-963. doi: 10.1124/dmd.118.080614. Epub 2018 Apr 17.

PMID:
29666154
3.

Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.

Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D, Ishiguro N, Taub ME, Sharma A, Ebner T, Müller F.

Br J Clin Pharmacol. 2018 Sep;84(9):1941-1949. doi: 10.1111/bcp.13609. Epub 2018 Jun 21.

4.

N-Methylation of BI 187004 by Thiol S-Methyltransferase.

Maw HH, Zeng X, Campbell S, Taub ME, Teitelbaum AM.

Drug Metab Dispos. 2018 Jun;46(6):770-778. doi: 10.1124/dmd.117.079764. Epub 2018 Mar 7.

PMID:
29514826
5.

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.

Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, Jungnik A, Gansser D, Ebner T, Müller F.

Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):69-80. doi: 10.1007/s13318-017-0427-9.

6.

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.

Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, Zimdahl-Gelling H, Gansser D, Wein M, Ebner T, Müller F.

Clin Pharmacol Ther. 2016 Sep;100(3):259-67. doi: 10.1002/cpt.406. Epub 2016 Jul 29.

7.
8.

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Review.

PMID:
25587128
9.

Sex-, Species-, and Tissue-Specific Metabolism of Empagliflozin in Male Mouse Kidney Forms an Unstable Hemiacetal Metabolite (M466/2) That Degrades to 4-Hydroxycrotonaldehyde, a Reactive and Cytotoxic Species.

Taub ME, Ludwig-Schwellinger E, Ishiguro N, Kishimoto W, Yu H, Wagner K, Tweedie D.

Chem Res Toxicol. 2015 Jan 20;28(1):103-15. doi: 10.1021/tx500380t. Epub 2015 Jan 5.

PMID:
25489797
10.

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.

Sane RS, Steinmann GG, Huang Q, Li Y, Podila L, Mease K, Olson S, Taub ME, Stern JO, Nehmiz G, Böcher WO, Asselah T, Tweedie D.

J Pharmacol Exp Ther. 2014 Nov;351(2):403-12. doi: 10.1124/jpet.114.218081. Epub 2014 Sep 9.

PMID:
25204339
11.

Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac.

Ramsden D, Tweedie DJ, Chan TS, Taub ME, Li Y.

Drug Metab Dispos. 2014 Mar;42(3):394-406. doi: 10.1124/dmd.113.055897. Epub 2013 Dec 23.

PMID:
24366904
12.

Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulation.

Li Y, Zhou J, Ramsden D, Taub ME, O'Brien D, Xu J, Busacca CA, Gonnella N, Tweedie DJ.

Drug Metab Dispos. 2014 Mar;42(3):384-93. doi: 10.1124/dmd.113.055863. Epub 2013 Dec 17.

PMID:
24346834
13.

Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herédi-Szabó K, Neuhoff S, Palm J, Balimane P, Zhang L, Jamei M, Hanna I, O'Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak AY, Perloff ES, Rajaraman G, Salphati L, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yamagata T, Lee CA.

Drug Metab Dispos. 2013 Jul;41(7):1367-74. doi: 10.1124/dmd.112.050542. Epub 2013 Apr 25.

14.

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H.

Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25.

15.

ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, Galetin A; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):64-79. doi: 10.1038/clpt.2013.45. Epub 2013 Feb 25. Review.

16.
17.

Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells.

Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M, Lee CA.

Drug Metab Dispos. 2011 Nov;39(11):2093-102. doi: 10.1124/dmd.111.040816. Epub 2011 Aug 17.

PMID:
21849517
18.

The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.

Hodge LS, Taub ME, Tracy TS.

Drug Metab Dispos. 2011 Nov;39(11):2013-6. doi: 10.1124/dmd.111.040790. Epub 2011 Aug 10.

PMID:
21832002
19.

Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.

Hodge LS, Taub ME, Tracy TS.

Biochem Pharmacol. 2011 Apr 1;81(7):950-6. doi: 10.1016/j.bcp.2011.01.016. Epub 2011 Feb 1.

PMID:
21291869
20.

Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.

Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, Castles MA, Robinson P.

Basic Clin Pharmacol Toxicol. 2011 Mar;108(3):163-70. doi: 10.1111/j.1742-7843.2010.00636.x. Epub 2010 Oct 27.

21.

Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.

Taub ME, Podila L, Ely D, Almeida I.

Drug Metab Dispos. 2005 Nov;33(11):1679-87. Epub 2005 Aug 10.

PMID:
16093365
22.

A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.

Zdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, Rasmussen MH, Ilondo MM.

Eur J Clin Pharmacol. 2003 Feb;58(10):683-8. Epub 2003 Feb 6.

PMID:
12610745
23.
24.

Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line.

Nielsen CU, Andersen R, Brodin B, Frokjaer S, Taub ME, Steffansen B.

J Control Release. 2001 Sep 11;76(1-2):129-38.

PMID:
11532319
25.

Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter.

Lepist EI, Kusk T, Larsen DH, Andersen D, Frokjaer S, Taub ME, Veski P, Lennernäs H, Friedrichsen G, Steffansen B.

Eur J Pharm Sci. 2000 Jul;11(1):43-50.

PMID:
10913752
26.

Stability, metabolism and transport of D-Asp(OBzl)-Ala--a model prodrug with affinity for the oligopeptide transporter.

Steffansen B, Lepist EI, Taub ME, Larsen BD, Frokjaer S, Lennernäs H.

Eur J Pharm Sci. 1999 Apr;8(1):67-73.

PMID:
10072480
27.
29.
30.
31.

Experience with the artificial urinary sphincter at Michigan.

Diokno AC, Taub ME.

J Urol. 1976 Oct;116(4):496-500.

PMID:
1053343

Supplemental Content

Support Center